104 related articles for article (PubMed ID: 9363981)
1. (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.
Moody TW; Leyton J; Coelho T; Jakowlew S; Takahashi K; Jameison F; Koh M; Fridkin M; Gozes I; Knight M
Life Sci; 1997; 61(17):1657-66. PubMed ID: 9363981
[TBL] [Abstract][Full Text] [Related]
2. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
3. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
4. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
5. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
Casibang M; Purdom S; Jakowlew S; Neckers L; Zia F; Ben-Av P; Hla T; You L; Jablons DM; Moody TW
Lung Cancer; 2001; 31(2-3):203-12. PubMed ID: 11165399
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
8. Regulation of VIP gene expression in general. Human lung cancer cells in particular.
Davidson A; Moody TW; Gozes I
J Mol Neurosci; 1996; 7(2):99-110. PubMed ID: 8873894
[TBL] [Abstract][Full Text] [Related]
9. [Effect of vasoactive intestinal peptide receptor antagonist VIPhybrid on the development of form deprivation myopia in chicks].
Wang PB; Wang H; Liu SZ; Jiang JJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 33(8):669-75. PubMed ID: 18772504
[TBL] [Abstract][Full Text] [Related]
10. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE
Life Sci; 2004 Jan; 74(11):1345-57. PubMed ID: 14706566
[TBL] [Abstract][Full Text] [Related]
11. The development of VIP-ellipticine conjugates.
Moody TW; Czerwinski G; Tarasova NI; Moody DL; Michejda CJ
Regul Pept; 2004 Dec; 123(1-3):187-92. PubMed ID: 15518911
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.
Moody TW; Leyton J; Garcia-Marin L; Jensen RT
Eur J Pharmacol; 2003 Aug; 474(1):21-9. PubMed ID: 12909192
[TBL] [Abstract][Full Text] [Related]
13. AH6809 antagonizes non-small cell lung cancer prostaglandin receptors.
Casibang M; Moody TW
Lung Cancer; 2002 Apr; 36(1):33-42. PubMed ID: 11891031
[TBL] [Abstract][Full Text] [Related]
14. VIP and breast cancer.
Moody TW; Leyton J; Gozes I; Lang L; Eckelman WC
Ann N Y Acad Sci; 1998 Dec; 865():290-6. PubMed ID: 9928023
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid down-regulates VPAC(1) receptors and TGF-beta 3 but up-regulates TGF-beta 2 in lung cancer cells.
Jakowlew SB; Zakowicz H; Moody TW
Peptides; 2000 Dec; 21(12):1831-7. PubMed ID: 11150643
[TBL] [Abstract][Full Text] [Related]
16. VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
Moody TW; Czerwinski G; Tarasova NI; Michejda CJ
Life Sci; 2002 Jul; 71(9):1005-14. PubMed ID: 12088760
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels.
Lee M; Jensen RT; Huang SC; Bepler G; Korman L; Moody TW
Peptides; 1990; 11(6):1205-9. PubMed ID: 1965032
[TBL] [Abstract][Full Text] [Related]
18. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
Gelber E; Granoth R; Fridkin M; Dreznik Z; Brenneman DE; Moody TW; Gozes I
Cancer; 2001 Oct; 92(8):2172-80. PubMed ID: 11596035
[TBL] [Abstract][Full Text] [Related]
19. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
20. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
